Pathological and therapeutic implications of omega-3 fatty acids in schizophrenia

The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention

Volumn , Issue , 2013, Pages 337-362

  Yao, Jeffrey K ^a,b,c   Reddy, Ravinder ^a,b   Condray, Ruth ^a   Long, Tao ^c   Haas, Gretchen ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895375390     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Akter K, Gallo DA, Martin SA, Myronyuk N, Roberts RT, Stercula K, Raffa RB. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia, J. Clin. Pharm. Therapeutics 2011; doi:10.1111/j.1365-2710.2011.01265.x.
2. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010; 67:146-154.
3. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003a; 62:195-204.
4. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, and Mahadik SP, Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003b; 53:56-64.
5. Bhatia HS, Agrawal R, Sharma S, Huo Y-X, Ying Z, Gomez-Pinilla F. Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS ONE 2011; 6: e28451. doi:10.1371/journal.pone.0028451.
6. Ballantyne CM. Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids. Curr. Atheroscler Rep. 1999; 1:6-8.
7. Basso, M.R., Bornstein, R.A., Lang, J.M. Practice effects on commonly used measures of executive function across twelve months. The Clinical Neuropsychologist 1999; 13:283-292.
8. Bentsen H, Solberg DK, Refsum H, Gran MJ, Bøhmer T, Torjesen PA, Halvorsen O, Lingjærde O. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol. Psychiatry 2011; 70:97-105.
9. Berger GE, et al. Implications of lipid biology for the pathogenesis of schizophrenia. Aust. N. Z. J. Psychiatry 2002; 36:355-366.
10. Berger GE, Proffitt T-M, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD. Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. J. Clin. Psychiatry 2007; 68:1867-1873.
11. Bourguignon A. Trial of evening primrose oil in the treatment of schizophrenia. L'Encephaale 1984; 10:241-250.
12. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging 2004; 8:163-174.
13. Brown AS, Susser ES. Prenatal Nutritional Deficiency and Risk of Adult Schizophrenia. Schizophr. Bull 2008; 34:1054-1063.
14. Brown, S. Excess mortality of schizophrenia. Brit. J. Psychiatry 1997; 171:502-508.
15. Brown S., Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999; 29:697-701.
16. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 2002; 112:298-304.
17. Byrne M, Agerbo E, Eaton WW, Mortensen PB. Soc. Psychiatry Psychiatr Epidemiol. 2004; 39:87-96.
18. Calder PC. Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Braz J. Med. Biol. Res. 1998; 31:467-490.
19. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr. Bull 2007; 33:661-664.
20. Carpenter Jr WT, Buchanan RW. Schizophrenia. N. Engl. J. Med. 1994; 330:681-690.
21. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001; 36, 937-944.
22. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006; 75:259-269.
23. Chilton RJ. Lipid and nonlipid benefits of statins. J. Am. Oseteopath. Assoc. 2003; 103:12-17.
24. Christinsen O, Christinsen E. Fat consumption and schizophrenia, Acta Psychiat. Scand. 1988; 78:587-591.
25. Church M, Jen K, Dowhan L, Adams B, Hotra J. Excess and deficient omega-3 fatty acid during pregnancy and lactation cause impaired neural transmission in rat pups. Neurotoxicol. Teratol. 2008; 30:107-117.
26. Condray R, Yao JK. Cognition, dopamine and bioactive lipids in schizophrenia. Frontiers in Bioscience 2011; S3: 298-330.
27. Connor WE. Importance of n-3 fatty acids in health and disease. Am. J. Clin. Nutr. 2000; 71(1 Suppl):171S-175S.
28. Crawford MA, Sinclair AJ, Nutritional influence in the evolution of mammalian brain, in: K. Elliott, J. Knight (Eds.), Lipids, Malnutrition and the Developing Brain, Ciba Foundation Symposia, No. 3, Excerpta Medica, Amsterdam, 1972; pp 267-287.
29. Cullen KR, Kumra S, Regan J, Westerman M, Schulz SC. Atypical antipsychotics for treatment of schizophrenia spectrum disorders. Psychiatric Times 2008; 25(3).
30. Dalmau A, Bergman B, Brismar B. Somatic morbidity in schizophrenia-a case control study. Public Health 1997; 111:393-397.
31. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991; 148:1474-1486.
32. de Clerck F, The role of serotonin in thrombogenesis. Clin. Physiol. Biochem. 1990; 8 (Suppl 3):40-49.
33. Delion S, Chalon S, Guilloteau D, Besnard J-C, Durand G. a-linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 1996; 66:1582-1591.
34. Delion S, Chalon S, Hérault J, Guilloteau D, Besnard J-C, Durand G. Chronic dietary -linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J. Nutr. 1994; 124:2466-2476.
35. du Bois TM, Deng C, Huang X-F. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog. Neuro-Psychopharmacol Biol. Psychiatry 2005; 29:878-888.
36. Emsley R, Myburgh C, Oosthuizen P, van Rensburgh SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002; 159:1596-1598.
37. Emsley R, Niehaus DJH, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM, Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) inpsychiatric patients: Results from a randomized, placebo-controlled trial, Psychiatry Res. 2008; 161:284-291.
38. Ernster L. Lipid peroxidation in biological membranes Mechanisms and implications. In: Active oxygens, lipid peroxides, and antioxidants, edited by Yagi K. New York, NY: CRC Press, 1993, pp 11-38.
39. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003; 69:393-399.
40. Fedorova I, Hussein N, Baumann MH, Martino CD, Salem Jr N. An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes Maze. Behavioral Neurosci. 2009; 123:196-205.
41. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001; 158:2071-2084.
42. Fenton WS, Hibbeln, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol Psyschiatry 2000; 47:8-21.
43. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 2006; 67: 1954-1967.
44. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am. J. Med. 2002; 113:625-629.
45. Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen RK. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol. Psychiatry 1987; 22:421-426.
46. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr. Res. 1995; 16:1-6.
47. Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int. Rev. Neurobiol 2002; 52:275-302.
48. Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, Skinner FS. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophr. Res. 1994; 12:53-61.
49. Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, HorrobinDF. Membrane fatty acids, niacin flushing and clinical parameters, Prostaglandins Leukot Essent Fatty Acids 1996; 55:9-15.
50. Goldberg TE, Keefe RSE, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010; 35:1053-1062.
51. Gottesman II, Shields J. Schizophrenia: the epigenetic puzzle. New York: Cambridge University Press. 1982.
52. Guillot N, Caillet E, Laville M, Calzada C, Lagarde M, Véricel E. Increasing intakes of the long-chain ω-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J. 2009; 23:2909-2916.
53. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do K. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA 2007; 104:16621-16626.
54. Haas GL, Castle DJ. Sex differences in schizophrenia. In: MS Keshavan, RM Murray (eds.), Neurodevelopment and Adult Psychopathology, New York: Cambridge University Press, 1998; pp 155-177.
55. Harper KN, Hibbeln JR, Deckelbaum R, Quesenberry Jr. CP, Schaefer CA, Brown AS. Maternal serum docosahexaenoic acid and schizophrenia spectrum disorders in adult offspring. Schizophr. Res. 2011; doi:10.1016/j.schres.2011.01.009.
56. Harris EC, Barraclough B. Excess mortality of mental disorder. Brit. J. Psychiatry 1998; 173:11-53.
57. Hayashi, N., Tashiro, T., Yammamori, H., Takagi, K., Morishima, Y., Otsubo, Y., Sugiura T, Furukawa K, Nitta H, Nakajima N, Suzuki N, Ito I. Effects of intravenous omega-3 and omega-6 fat emulsion on cytokine production and delayed type hypersensitivity in burned rats receiving total parenteral nutrition. J. Parenter Enteral Nutr. 1998; 22:363-367.
58. Hedelin M, Löf M, Olsson M, Lewander T, Nilsson B, Hultman CM, Weiderpass E. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry 2010; 10:38.
59. Heron D, Shinitzky M, Hershkowitz M, Samuel D, Lipid fluidity markedly modulates the binding of serotonin to mouse brain membrane. Proc. Natl. Acad. Sci. USA 1980; 77: 7463-7467.
60. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry 2003; 53:431-441.
61. Hibbeln JR, Salem N Jr, Dietary polyunsaturated fatty acids and depression, Am. J. Clin. Nutr 1995; 62:1-9.
62. Hibblen JR, Umhau JC, Linnoila M, George DT, Regan PW, Shoaf SE, Vaughan MR, Rawlings R, Salem N Jr. A replication study of violent and nonviolent subjects: Cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids, Biol. Psychiatry 1998; 44:243-249.
63. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. Schizophr. Res. 2004; 68:49-63.
64. Horrobin DF. Schizophrenia, a biochemical disorder? Biomedicine 1980; 32:54-55.
65. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998; 30:193-208.
66. Horrobin DF. Omega-3 fatty acid for schizophrenia. Am. J. Psychiatry 2003; 160:1.
67. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 1991; 30:795-805.
68. Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, Glen AI, Glen E, Spellman M, Bates C. Essential fatty acids in plasma phospholipids in schizophrenics. Biol. Psychiatry 1989; 25: 562-568.
69. Horrobin DF, Glen AI, Hudson CJ. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: The relationship between dyslexia and schizophrenia. Med. Hypotheses 1995; 45:605-613.
70. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr. Bull 2009; 35:549-562.
71. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol. Med. Monogr. Suppl. 1992; 20:1-97.
72. Javitt DC, Laruelle M. Neurochemical theories. In: Text Book of Schizophrenia, edited by Lieberman JA, Stroup TS, and Perkins DO, Washington DC: The American Psychiatric Publishing, 2006, pp 85-116.
73. Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol. Psychiatry 1991; 30:357-362.
74. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res 2010; 175:47-53.
75. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr. Bull 1993; 19:287-302.
76. Kapoor S. Omega-3 fatty acids and their rapidly evolving role in the management of psychiatric disorders. Prog. Neuro-psychopharmacol Biol. Psychiatry 2008
77. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 2005; 57:688-691.
78. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002; 58:1-10.
79. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, Leff JP, Mallett RM, Harrison GL, Murray RM, Jones PB. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: Findings from the 3-center AESOP study. Arch. Gen. Psychiatry 2006; 63:250-258.
80. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Murray RM, Jones PB. Neighbourhood variation in the incidence of psychotic disorders in Southeast London. Soc. Psychiatry Psychiatr Epidemiol. 2007; 42:438-445.
81. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106:2747-2757.
82. Laye S, Polyunsaturated fatty acids, neuroinflammation and wellbeing. Prostaglandins Leukot Essent Fatty Acids 2010; 82:295-303.
83. Lee S, Gura KM, Kim S, Arsenault DA, Bistrian BR, Puder M. Current clinical applications of Ω-6 and Ω-3 fatty acids. Nutr Clin Pract 2006; 21:323-341.
84. Lee KW, Lip GYH. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJ Med. 2003; 96:465-480.
85. Légaré N, Brosseau E, Joyal CC. Omega-3 and violence in schizophrenia. Schizophr. Res. 2007; 96:269.
86. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophr. Bull 1993; 19:371-429.
87. Maes M, Christophe A, Bosmans E, Lin A, Neels H. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol. Psychiatry 2000; 47:910-920.
88. Mahadik SP, Mukherjee S, Correnti E, Kelkar HS, Wakade CG, Costa RM, Scheffer R. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naïve patients at the onset of psychosis. Schizophr. Res. 1994; 13:239-247.
89. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 1996; 63:133-142.
90. Mahadik SP, Yao JK. Phospholipids in schizophrenia. In: Textbook of Schizophrenia. Eds: Lieberman JA, Stroup TS, Perkins DO, Stroup TS, Perkins DO, The American Psychiatric Publishing, Inc., Washington, DC, 2006; pp 117-135.
91. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 2007; 31:12-26.
92. Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr. Res. 1995; 18:85-86.
93. McBride PA, Anderson GM, Hertzig M, Sweeney JA, KreAm. J., Cohen DJ, Mann JJ, Serotonergic responsivity in male young adults with autistic disorder. Arch. Gen. Psychiatry 1989; 46:213-221.
94. McNamara RK. Omega-3 fatty acid deficiency: A preventable risk factor for schizophrenia? Schizophr. Res. 2011; 129:215-216.
95. McNamara RK, Able JA, Jandacek R et al. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: Evidence for augmented biosynthesis. Schizophr. Res. 2009; 107:150-157.
96. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 2006; 75:329-349.
97. McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, Stanford KE. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medication. Schizophr. Res. 2007; 91:37-50.
98. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69:413-419.
99. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morill-Labrode A, Dinarello CA, Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women. J. Nutr. 1991; 121:547-555.
100. Murray CJL, Lopez AD. The Global Burden of Disease. Geneva, World Health Organization, Harvard School of Public Health, World Bank, 1996.
101. Nilsson A, Horrobin DF, Rosengren A, Waller L, Adlerberth A, Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population, a study of men born in 1933. Prostaglandins Leukot Essent Fatty Acids 1996; 55:83-87.
102. Noponen M, Sanfilipo M, Samanich K, Ryer HKG, Angrist B, Wolkin A, Duncan E, Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry 1993; 34:641-649.
103. Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, J Masliah J, and Wolf C. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res. 2009; 169:91-96.
104. Ohara K. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuro-psychopharmacol Biol. Psychiatry 2007; 31:469-474.
105. O'Keefe JH, Harris WS. From inuit to implementation: omega-3 fatty acids come of age. Mayo Clinic Proc. 2000; 75:607-614.
106. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris JM, Zisook S, Jeste DV. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997; 11:437-446.
107. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br. J. Psychiat. 2004; 184:404-408.
108. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr. J. Psychiatry Relat. Sci. 2008; 45:19-25.
109. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two-double blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001; 49:243-251.
110. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicopentaenoate in patients with persistent schizophrenic symptoms. J. Psychiat. Res. 2002; 36:7-18.
111. Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in eyrthrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotr Essent Fatty Acids 1996; 55:71-75.
112. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995; 29:227-232.
113. Perica MM, Delaš I. Essential fatty Aacids and psychiatric disorders. Nutr. Clin. Pract. 2011; 26:409-425.
114. Pettegrew JW, Keshavan M, Minshew NJ, McClure RJ. 31P Magnetic Resonance Spectroscopy Study of Metabolic Alterations in Schizophrenia and Neurodevelopment. In: Magnetic Resonance Spectroscopy in Psychiatric Brain Disorders. Nasrallah HA, Pettegrew JW, editors. Washington DC: American Psychiatric Press, 1994, pp 49-83.
115. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, John DF England the Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern Med. 2002; 137:581-585.
116. Picchioni MM, Murray RM. Schizophrenia. Brit. Med. J. 2007; 335:91-95.
117. Ponizovsky AM, Modai I, Nechamkin Y, Barshtein G, Ritsner MS, Yedgar S, Lecht S, Bergelson LD. Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. Schizophr. Res. 2001; 52:121-126.
118. Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, Hajnal JV, Bydder GM. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Intl. J. Clin. Pract. 2000; 54:57-63.
119. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first-episode schizophrenia at neuroleptic-naïve baseline. Schizophr. Bull 2004; 30:901-911.
120. Reddy RD, Keshavan MS, Yao JK. Blunted serotonergic responsivity in platelets from neuroleptic-naive patients at first episode of schizophrenia. Schizophr. Res. 2007; 90:81-85.
121. Reddy, R., Fleet-Michaliszyn, S., Condray, R., Yao, J.K., Keshavan, M.S., Reddy, R. Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: A preliminary study. Prostaglandins Leukotr Essential Fatty Acids 2011; 84:79-83.
122. Richardson AJ, Easton T, McDaid AM, Hall JA, Montgomery P, Clisby C, Puri BK. Essential fatty acids in dyslexia: theory, evidence and clinical trails. In: Phospholipid Spectrum Disorder in Psychiatry. Peet M, Glen I, and Horrobin DF, editors. Marius Press, Lancashire UK, 1999, pp 225-241.
123. Richardson AJ, Easton T, Puri BK. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Europ Neuropsychopharma 2000; 10:189-193.
124. Roy S, Kale A, Dangat K, Sable P, Kulkarni A, Joshi S. Maternal micronutrients (folic acid and vitamin B12) and omega 3 fatty acids: Implications for neurodevelopmental risk in the rat offspring. Brain Development 2011; In press.
125. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Arch. Gen. Psychiatry 1997; 54:487-494.
126. Ryan AS, Astwood JD, Gautier S, Kuratko CN, Nelson EB, Salem Jr N. Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: A review of human studies, Prostaglandins Leukot Essent Fatty Acids 2010; 82:305-314.
127. Rybakowski J, Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry 1991; 29:834-836.
128. Saha S, Chant D, WelhAm. J., McGrath J. A systematic review of the prevalence of schizophrenia. PloS Med. 2005; 2:413-33.
129. Saunders JC. Families living with severe mental illness: A literature review. Issues in Mental Health Nursing 2003; 24:175-198.
130. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol. Psychiatry 2004; 56:41-45.
131. Scorza FA, Cysneirosb RM, Terra VC, Scorza CA, Cavalheiro EA, Ribeiro MO, GattazWF. Omega-3 consumption and sudden cardiac death in schizophrenia, Prostaglandins Leukotr Essential Fatty Acids 2009; 81;241-245.
132. Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophr. Res. 1998; 29:158.
133. Sims A. Symptoms in the mind: an introduction to descriptive psychopathology. Philadelphia: W. B. Saunders; 2002.
134. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E. The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study, Prog Neuro-Psychopharmacol Biol. Psychiatry 2007; 31:1493-1499.
135. Skosnik PD, Yao JK. From membrane phospholipid defects to altered neurotransmission: Is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 2003; 69:367-384.
136. Smith RS. The macrophage theory of depression. Med. Hypotheses 1991; 35:298-306.
137. Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). Am. Fam. Physician 2010; 82:338-339.
138. Soulairac A. Lambinet H., Neuman JC. Schizophrenia and PGs: Therapeutic effects of PG precursors in the form of evening primrose oil. Ann. Med. Psychol. 1983; 8:883-890.
139. Soyland E, Lea T, Sandstand B, Drevon A. Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with infammatory skin disease. Eur. J. Clin. Invest. 1994; 24:236-242.
140. Stokes C, Peet M. Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr. Neurosci. 2004; 7:247-249.
141. Stordy B. Long-chain fatty acids in the management of dyslexia and dyspraxia. In: Phospholipid Spectrum Disorder in Psychiatry. Peet M, Glen I, Horrobin DF, editors. Lancashire (UK): Marius Press, 1999; pp 251-260.
142. Strauss JS, Carpenter Jr WT. Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch. Gen. Psychiatry 1977; 34:159-163.
143. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Eur. Neuropsychopharmacology 2001; 11:295-299.
144. Sumiyoshi T, Higuchi Y, Matsui M, Itoh H, Uehara T, Itoh T, Arai H, Takamiya C, Suzuki M, Kurachi M. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res. 2011; 186:23-27.
145. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" What we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008; 102:1-18.
146. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009; 110:1-23.
147. Tavani A, Pelucchi C, Negri E, Bertuzzi M, Vecchia C. N-3 Polyunsaturated Fatty Acids, Fish, and Nonfatal Acute Myocardial Infarction. Circulation 2001; 104:2269-2272.
148. Tien AY, Eaton WW, Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch. Gen. Psychiatry 1992; 49:37-46.
149. Tkachev D, Mimmack M, Huffaker S, Ryan M, Bahn S. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int. J. Neuropsychopharmacol. 2007; 10:557-563.
150. Torpy J, Lynm C, Glass R. Eating fish: health benefits and risks. JAMA 2006; 296:1926.
151. Vaddadi KS, Gilleard CJ, Mindhyam RH, Butler R. A controlled trial of prostaglandin El precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology 1986; 88:361-367.
152. Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia, Psychiatr Res. 1989; 27:313-323.
153. van Os J, Kapur S. Schizophrenia. Lancet. 2009; 374:635-645.
154. Walker NP, Fox HC, Whalley LJ. Lipids and schizophrenia. Br. J. Psychiatry 1999; 174:101-104.
155. Whalley LJ, Deary IJ, Starr JM, Wahle KW, Rance KA, Bourne VJ, Fox HC. N-3 fatty acid erythrocyte membrane content, APOE ε4, and cognitive variation: an observational follow-up study in late adulthood. Am. J. Clin. Nutr 2008; 87:449-454.
156. Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am. J. Psychol. 1986; 143:912-914.
157. World Health Organization (WHO). Age-standardized DALYs per 100,000 by cause, and Member State, 2004.
158. Yao JK. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In Phospholipid Spectrum Disorders in Psychiatry and Neurology (2nd edition), Peet M, Glen I, Horrobin DF. (eds.), Marius Press, Lancashire, UK, 2003, pp 193-212.
159. Yao JK, Keshavan MS. Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View. Antioxidants Redox Signaling 2011; 15:2011-2035.
160. Yao JK, Leonard S, Reddy R. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000; 42:7-17.
161. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essential Fatty Acids 2004; 71:171-176.
162. Yao JK, Sistilli CG, van Kammen DP. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69:429-436.
163. Yao JK, van Kammen DP. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr. Res. 1994; 11:209-216.
164. Yao JK, van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int. Rev. Neurobiol. 2004; 59:297-326.
165. Yao JK, van Kammen DP, Moss HB, Sokulski DE, A decreased serotonergic responsivity in platelets of drug-free schizophrenic patients. Psychiatry Res. 1996; 63:123-132.
166. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 1994a; 13:217-226.
167. Yao JK, van Kammen DP, Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 1994b; 13:227-232.
168. Zimmer L, Delpal S, Guilloteau D, Aïoun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci. Letters 2000; 284:25-28.
169. Zimmer L, Hembert S, Durand G., Breton P, Guilloteau D, Besnard JC, Chalon S. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci. Letters 1998; 240:177-181.